The global cellulite treatment market size is calculated at USD 2.68 billion in 2025 and is forecasted to reach around USD 6.86 billion by 2034, accelerating at a CAGR of 11.07% from 2025 to 2034. The North America cellulite treatment market size surpassed USD 890 million in 2024 and is expanding at a CAGR of 11.10% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Cellulite Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Cellulite Treatment Market, by Procedure Type
8.1.1 Non-invasive
8.1.1.1. Market Revenue and Forecast
8.1.2. Topical
8.1.2.1. Market Revenue and Forecast
8.1.3. Minimally Invasive
8.1.3.1. Market Revenue and Forecast
9.1. Cellulite Treatment Market, by Cellulite Type
9.1.1. Soft Cellulite
9.1.1.1. Market Revenue and Forecast
9.1.2. Edematous Cellulite
9.1.2.1. Market Revenue and Forecast
9.1.3. Hard Cellulite
9.1.3.1. Market Revenue and Forecast
10.1. Cellulite Treatment Market, by End-Use
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast
10.1.2. Clinics & Beauty Centers
10.1.2.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Procedure Type
11.1.2. Market Revenue and Forecast, by Cellulite Type
11.1.3. Market Revenue and Forecast, by End-Use
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Procedure Type
11.1.4.2. Market Revenue and Forecast, by Cellulite Type
11.1.4.3. Market Revenue and Forecast, by End-Use
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Procedure Type
11.1.5.2. Market Revenue and Forecast, by Cellulite Type
11.1.5.3. Market Revenue and Forecast, by End-Use
11.2. Europe
11.2.1. Market Revenue and Forecast, by Procedure Type
11.2.2. Market Revenue and Forecast, by Cellulite Type
11.2.3. Market Revenue and Forecast, by End-Use
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Procedure Type
11.2.4.2. Market Revenue and Forecast, by Cellulite Type
11.2.4.3. Market Revenue and Forecast, by End-Use
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Procedure Type
11.2.5.2. Market Revenue and Forecast, by Cellulite Type
11.2.5.3. Market Revenue and Forecast, by End-Use
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Procedure Type
11.2.6.2. Market Revenue and Forecast, by Cellulite Type
11.2.6.3. Market Revenue and Forecast, by End-Use
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Procedure Type
11.2.7.2. Market Revenue and Forecast, by Cellulite Type
11.2.7.3. Market Revenue and Forecast, by End-Use
11.3. APAC
11.3.1. Market Revenue and Forecast, by Procedure Type
11.3.2. Market Revenue and Forecast, by Cellulite Type
11.3.3. Market Revenue and Forecast, by End-Use
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Procedure Type
11.3.4.2. Market Revenue and Forecast, by Cellulite Type
11.3.4.3. Market Revenue and Forecast, by End-Use
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Procedure Type
11.3.5.2. Market Revenue and Forecast, by Cellulite Type
11.3.5.3. Market Revenue and Forecast, by End-Use
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Procedure Type
11.3.6.2. Market Revenue and Forecast, by Cellulite Type
11.3.6.3. Market Revenue and Forecast, by End-Use
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Procedure Type
11.3.7.2. Market Revenue and Forecast, by Cellulite Type
11.3.7.3. Market Revenue and Forecast, by End-Use
11.4. MEA
11.4.1. Market Revenue and Forecast, by Procedure Type
11.4.2. Market Revenue and Forecast, by Cellulite Type
11.4.3. Market Revenue and Forecast, by End-Use
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Procedure Type
11.4.4.2. Market Revenue and Forecast, by Cellulite Type
11.4.4.3. Market Revenue and Forecast, by End-Use
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Procedure Type
11.4.5.2. Market Revenue and Forecast, by Cellulite Type
11.4.5.3. Market Revenue and Forecast, by End-Use
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Procedure Type
11.4.6.2. Market Revenue and Forecast, by Cellulite Type
11.4.6.3. Market Revenue and Forecast, by End-Use
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Procedure Type
11.4.7.2. Market Revenue and Forecast, by Cellulite Type
11.4.7.3. Market Revenue and Forecast, by End-Use
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Procedure Type
11.5.2. Market Revenue and Forecast, by Cellulite Type
11.5.3. Market Revenue and Forecast, by End-Use
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Procedure Type
11.5.4.2. Market Revenue and Forecast, by Cellulite Type
11.5.4.3. Market Revenue and Forecast, by End-Use
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Procedure Type
11.5.5.2. Market Revenue and Forecast, by Cellulite Type
11.5.5.3. Market Revenue and Forecast, by End-Use
12.1. Cutera
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Tanceuticals
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Merz Pharmaceuticals, LLC
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Candela Corporation
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Nestle
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Inceler Medikal Co Ltd.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Mentor Worldwide LLC
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Shanghai Fosun Pharmaceutical (Group) Co. Ltd.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Zimmer Aesthetics
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Allergan
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample